Company Filing History:
Years Active: 2008
Title: Noriko Otani: Innovator in Cancer Therapeutics
Introduction
Noriko Otani is a prominent inventor based in Gunma, Japan. She has made significant contributions to the field of cancer therapeutics, particularly through her innovative work on antibodies targeting tumor cells. Her research focuses on developing effective treatments for various malignant tumors.
Latest Patents
Noriko Otani holds a patent for an Anti-A33 antibody. This invention provides an antibody or an antibody fragment that can bind to A33, specifically targeting A33-expressing tumor cells. The antibody utilizes antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) based on the immune system. Notably, this invention does not produce human anti-human antibodies (HAHA). The preventive or therapeutic agent developed from this antibody is aimed at treating various malignant tumors, including solid tumors that are currently challenging to manage.
Career Highlights
Noriko Otani is associated with Kirin Pharma Kabushiki Kaisha, where she continues her research and development efforts. Her work has been instrumental in advancing cancer treatment options and improving patient outcomes.
Collaborations
Noriko collaborates with esteemed colleagues, including Shiro Kataoka and Takafumi Tomura. Their combined expertise enhances the research and development process, leading to innovative solutions in cancer therapeutics.
Conclusion
Noriko Otani's contributions to the field of cancer therapeutics through her patented Anti-A33 antibody exemplify her dedication to improving treatment options for patients with malignant tumors. Her work continues to inspire advancements in medical research and innovation.